Sort   by:  
 Page size 
UnknownPathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.
Not available
S-EPMC10809386 | biostudies-literature
UnknownInfluence of primary tumor location and resection on survival in metastatic colorectal cancer.
Not available
S-EPMC7667454 | biostudies-literature
UnknownImplementation and use of whole exome sequencing for metastatic solid cancer.
Not available
S-EPMC7000332 | biostudies-literature
UnknownIn-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response.
Not available
S-EPMC7415635 | biostudies-literature
UnknownRadiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer.
Not available
S-EPMC7563314 | biostudies-literature
UnknownCorrigendum to "Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer": [ESMO Open 3 (2018) e000375].
Not available
S-EPMC10006516 | biostudies-literature
UnknownEvaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.
Not available
S-EPMC8183202 | biostudies-literature
UnknownPathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Not available
S-EPMC10587331 | biostudies-literature
UnknownImmune classifications with cytotoxic CD8+ and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.
Not available
S-EPMC5486170 | biostudies-literature
UnknownOptimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
Not available
S-EPMC6593525 | biostudies-literature
Sort   by:  
 Page size